Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 3, 2014, Pages 309-317

  Affolter, Kristina ^a   Tamm, Michael ^a   Jahn, Kathleen ^a   Halter, Jörg ^a   Passweg, Jakob ^a   Hirsch, Hans H ^b   Stolz, Daiana ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bronchoscopy; Immunosuppression; Invasive pulmonary aspergillosis

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; GALACTOMANNAN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; MANNAN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BRONCHOSCOPY; FUNGAL CELL WALL; GOLD STANDARD; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; LUNG LAVAGE; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SYSTEMIC MYCOSIS; CHEMOPROPHYLAXIS; FEMALE; HEMATOLOGIC DISEASE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; ISOLATION AND PURIFICATION; LUNG ASPERGILLOSIS; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SWITZERLAND;

BRONCHOSCOPY; IMMUNOSUPPRESSION; INVASIVE PULMONARY ASPERGILLOSIS;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHEMOPREVENTION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; LOGISTIC MODELS; MALE; MANNANS; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SWITZERLAND;

EID: 84907297612     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201403-0431OC     Document Type: Article

References (31)

1. Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012; 65:453-464.
2. Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 2011;54:e301-e312.
3. Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci R, Delia M, Nosari A, Bonini A, Cattaneo C, et al.; SEIFEM GROUP (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne). Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses 2014;57:342-350.
4. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, et al.; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:5111-5118.
5. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-1075.
6. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008;47:1176-1184.
7. Almyroudis NG, Segal BH. Prevention and treatment of invasive fungal diseases in neutropenic patients. Curr Opin Infect Dis 2009;22: 385-393.
8. Buess M, Cathomas G, Halter J, Junker L, Grendelmeier P, Tamm M, Stolz D. Aspergillus-PCR in bronchoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients. BMC Infect Dis 2012;12:237.
9. Schwarzinger M, Sagaon-Teyssier L, Cabaret O, Bretagne S, Cordonnier C, PREVERT Investigators. Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. PLoS ONE 2013;8:e65776.
10. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
11. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813-1821.
12. Posteraro B, Torelli R, De Carolis E, Posteraro P, Sanguinetti M. Update on the laboratory diagnosis of invasive fungal infections. Mediterranean J Hematol Infect Dis 2011;3:e2011002.
13. Park SY, Lee SO, Choi SH, Sung H, Kim MN, Choi CM, Hong SB, Oh YM, Shim TS, Koh Y, et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect 2010;61:492-498.
14. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42: 1417-1427.
15. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CM. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008;4: CD007394.
16. Weisser M, Rausch C, Droll A, Simcock M, Sendi P, Steffen I, Buitrago C, Sonnet S, Gratwohl A, Passweg J, et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005;41:1143-1149.
17. Bergeron A, Belle A, Sulahian A, Lacroix C, Chevret S, Raffoux E, Arnulf B, Socié G, Ribaud P, Tazi A. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 2010;137:410-415.
18. Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010;138:817-824.
19. Heng SC, Morrissey O, Chen SC, Thursky K, Manser RL, Nation RL, Kong DC, Slavin M. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol [online ahead of print] 25 Jun 2013; DOI: 10.3109/1040841X.2013.804033.
20. Luong ML, Filion C, Labbé AC, Roy J, Pépin J, Cadrin-Tourigny J, Carignan S, Sheppard DC, Laverdière M. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis 2010;68:132-139.
21. Racil Z, Kocmanova I, Toskova M, Buresova L, Weinbergerova B, Lengerova M, Rolencova M, Winterova J, Hrncirova K, Volfova P, et al. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis 2011;15:e874-e881.
22. Affolter K, Tamm M, Jahn K, Halter J, Passweg J, Hirsch HH, Stolz D. Galactomannan in the bronchoalveolar lavage for diagnosing invasive fungal disease. To be presented at the European Respiratory Society Annual Meeting 2014. Sept 6-10, 2014, Munich, Germany.
23. Stolz D, Kurer G, Meyer A, Chhajed PN, Pflimlin E, Strobel W, Tamm M. Propofol versus combined sedation in flexible bronchoscopy: a randomised non-inferiority trial. Eur Respir J 2009;34:1024-1030.
24. Stolz D, Stulz A, Müller B, Gratwohl A, Tamm M. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest 2007;132:504-514.
25. Sulahian A, Tabouret M, Ribaud P, Sarfati J, Gluckman E, Latge JP, Derouin F. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996;15:139-145.
26. Avni T, Levy I, Sprecher H, Yahav D, Leibovici L, Paul M. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol 2012;50: 3652-3658.
27. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-1769.
28. Reinwald M, Hummel M, Kovalevskaya E, Spiess B, Heinz WJ, Vehreschild JJ, Schultheis B, Krause SW, Claus B, Suedhoff T, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 2012;67:2260-2267.
29. Nguyen MH, Leather H, Clancy CJ, Cline C, Jantz MA, Kulkarni V, Wheat LJ, Wingard JR. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 2011;17: 1043-1050.
30. Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, Viscoli C. Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012;67:1746-1748.
31. Donnelly JP. Defining invasive aspergillosis: what the revised EORTC/MSG definitions have in store. In: Pasqualotto AC, editor. Aspergillosis: from diagnosis to prevention. New York: Springer; 2010. pp. 423-435.